About the Authors

R. Queiro-Silva

Contributed equally to this work with: R. Queiro-Silva, I. Belinchón-Romero

Roles Conceptualization, Investigation, Methodology, Supervision, Writing – review & editing

rubenque7@yahoo.es

Affiliation Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain

A. López-Ferrer

Roles Investigation, Writing – review & editing

Affiliation Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

M. Ferran i Farrés

Roles Investigation, Writing – review & editing

Affiliation Dermatology Department, Hospital del Mar, Barcelona, Spain

R. Rivera-Díaz

Roles Investigation, Writing – review & editing

Affiliation Dermatology Department, Hospital 12 de octubre, Universidad Complutense, Madrid, Spain

D. Vidal-Sarro

Roles Investigation, Writing – review & editing

Affiliation Dermatology Department, Hospital de Sant Joan Despí Moisés Broggi, Barcelona, Spain

L. Rodríguez Fernández-Freire

Roles Investigation, Writing – review & editing

Affiliation Dermatology Department, Hospital Universitario Virgen del Rocío, Seville, Spain

P. de la Cueva-Dobao

Roles Investigation, Writing – review & editing

Affiliation Dermatology Department, Hospital Universitario Infanta Leonor, Madrid, Spain

J. Santos-Juanes

Roles Investigation, Writing – review & editing

Affiliation Dermatology Department, Hospital Universitario Central de Asturias, Oviedo, Spain

V. Rocamora-Duran

Roles Investigation, Writing – review & editing

Affiliation Dermatology Department, Hospital de Manacor, Palma de Mallorca, Spain

L. Gómez-Labrador

Roles Writing – review & editing

Affiliation Novartis Farmacéutica S.A., Barcelona, Spain

I. Belinchón-Romero

Contributed equally to this work with: R. Queiro-Silva, I. Belinchón-Romero

Roles Conceptualization, Investigation, Methodology, Supervision, Writing – review & editing

Affiliation Dermatology Department, Hospital General Universitario Dr. Balmis de Alicante-ISABIAL, Universidad Miguel Hernández, Alicante, Spain

on behalf of the PURE-4 Study Group

Membership of the PURE-4 Study Group is provided in the acknowledgments.

Competing Interests

I have read the journal’s policy and the authors of this manuscript have the following competing interests: Rubén Queiro-Silva has received fees as a consultant, speaker, and project coordinator from the following pharmaceutical companies: AbbVie, Lilly, UCB, Janssen, Pfizer, Amgen, and Novartis, and has received grants from Janssen, Novartis, and AbbVie. Anna López-Ferrer has received fees for her participation as a member of scientific committees, consultant and/or speaker, and has received grants for research or participation in clinical trials from the following pharmaceutical companies (but not in relation to this manuscript): AbbVie, Almirall SA, Amgen, BMS, Boehringer Ingelheim, Janssen, LEO Pharma, MSD, Eli Lilly, Novartis, and UCB Pharma. Marta Ferran i Farrés has received fees as a consultant and/or speaker and has participated in clinical trials sponsored by the following pharmaceutical companies: Johnson & Johnson Innovative Medicine, Eli Lilly, Novartis, Pfizer-Wyeth, MSD, AbbVie, Celgene, BMS, Leo-Pharma, UCB, and Almirall SA. Raquel Rivera-Díaz has received fees as a consultant and/or speaker and has participated in clinical trials sponsored by the following pharmaceutical companies: AbbVie, Almirall SA, Amgen, Boehringer, BMS, Janssen Pharmaceuticals Inc, Eli Lilly, Leo-Pharma, Novartis, Pfizer-Wyeth, and UCB. David Vidal-Sarro has received fees as a consultant and/or speaker and has participated in clinical trials sponsored by the following pharmaceutical companies: AbbVie, Celgene, Eli Lilly, Janssen Pharmaceuticals Inc, Novartis, Gebro Pharma, Leo-Pharma, and UCB. Lourdes Rodríguez Fernández-Freire has received fees as a consultant and/or from the following pharmaceutical companies: AbbVie, Janssen Pharmaceuticals Inc, MSD, Pfizer-Wyeth, Novartis, Celgene, Almirall SA, Eli Lilly, and Leo-Pharma. Pablo de la Cueva-Dobao has received fees as a consultant and/or speaker and has participated in clinical trials sponsored by the following pharmaceutical companies: AbbVie, Almirall SA, Astellas Pharma, Biogen Inc., Boehringer Ingelheim, Celgene, Janssen Pharmaceuticals Inc, LEO Pharma, Eli Lilly, MSD, Novartis, Pfizer, and UCB. Jorge Santos-Juanes has received fees as a consultant and/or speaker from the following pharmaceutical companies: Novartis, Eli Lilly, Janssen Pharmaceuticals Inc, AbbVie, Amgen, and Sanofi. Vicenç Rocamora-Duran has received fees as a consultant and/or speaker from the following pharmaceutical companies: Janssen Pharmaceuticals Inc, Eli Lilly, AbbVie, Almirall SA, Amgen, and Novartis. Lara Gómez-Labrador is an employee of Novartis in Spain. Isabel Belinchón-Romero has received fees as a consultant and/or speaker and has participated in clinical trials sponsored by the following pharmaceutical companies whose therapeutic armamentarium includes drugs used to treat psoriasis: Janssen Pharmaceuticals Inc, Almirall SA, Lilly, AbbVie, Novartis, Celgene, Biogen, Amgen, Leo-Pharma, Pfizer-Wyeth, BMS, UCB, and MSD.